Last reviewed · How we verify

Xu jianmin — Portfolio Competitive Intelligence Brief

Xu jianmin pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
chemotherapy of mFOLFOX6 or FOLFIRI chemotherapy of mFOLFOX6 or FOLFIRI marketed Combination chemotherapy regimen Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin) Oncology
oxaliplatin+Leucovorin+5-FU oxaliplatin+Leucovorin+5-FU phase 3 Platinum-based chemotherapy DNA Oncology
FUDR +oxaliplatin FUDR +oxaliplatin phase 3 Chemotherapy combination (fluoropyrimidine + platinum agent) Thymidylate synthase (FUDR); DNA (oxaliplatin cross-linking) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Sun Yat-sen University · 2 shared drug classes
  2. Federation Francophone de Cancerologie Digestive · 2 shared drug classes
  3. Hoffmann-La Roche · 2 shared drug classes
  4. Sixth Affiliated Hospital, Sun Yat-sen University · 2 shared drug classes
  5. Zhejiang Cancer Hospital · 2 shared drug classes
  6. AstraZeneca · 2 shared drug classes
  7. Associazione Volontari Pazienti Oncologici · 1 shared drug class
  8. Alliance for Clinical Trials in Oncology · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xu jianmin:

Cite this brief

Drug Landscape (2026). Xu jianmin — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xu-jianmin. Accessed 2026-05-17.

Related